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Abstract
Inhibitors of histone deacetylases have been shown
to enhance the sensitivity of cancer cells to tumor
necrosis factor–related apoptosis-inducing ligand
TRAIL-mediated cytotoxicity. Valproic acid (VA), a
commonly used antiepileptic agent whose pharmaco-
kinetics and toxicity profiles are well described, is a
histone deacetylase inhibitor. This project aims to
evaluate if VA can potentiate Apo2L/TRAIL–mediated
cytotoxicity in cultured thoracic cancer cells and to elu-
cidate the underlying molecular mechanism respon-
sible for this effect. VA sensitized cultured thoracic
cancer cells to Apo2L/TRAIL, as indicated by a 4-fold
to a >20-fold reduction of Apo2L/TRAIL IC50 values
in combination-treated cells. Although VA (0.5–5 mM)
or Apo2L/TRAIL (20 ng/ml) induced less than 20% cell
death, VA + Apo2L/TRAIL combinations caused 60%
to 90% apoptosis of cancer cells. Moreover, substantial
activation of caspases 8, 9, and 3, which was observed
only in cells treated with the drug combinations, was
completely suppressed by Bcl2 overexpression or by
the caspase 9 inhibitor. Both the caspase 9 inhibitor
and Bcl2 completely abrogated the substantial cyto-
toxicity and apoptosis induced by this combination,
thus highlighting the pivotal role of the type II path-
way in this process. These findings provide a rationale
for the development of VA and Apo2L/TRAIL combina-
tion as a novel molecular therapeutic regimen for tho-
racic cancers.
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Introduction
Tumor necrosis factor–related apoptosis-inducing ligand
(TRAIL) is expressed by natural killer cells, T cells, neutro-
phils and monocytes in responses to interferons and play
physiologic roles of tumor surveillance and immune regulation
[1,2]. The extracellular domain of membrane-bound TRAIL can
be proteolytically cleaved from the cell surface to generate
soluble TRAIL. The soluble TRAIL extracellular domains homo-
trimerize through an internal zinc atom bound to the cysteine
residue at position 230 of each subunit, and this process is
crucial for trimer stability and biologic activity [3,4]. The receptor
repertoire of TRAIL is complex and consists of five members:
two functional death receptors (DR4, DR5) that contain a
conserved intracellular death domain motif; two decoy recep-
tors (DcR1, DcR2) that can bind TRAIL but lack the functional
intracellular death domain and are thus incapable of transduc-
ing a death signal; and the fifth is a soluble protein [osteopro-
tegerin (OPG)] that binds TRAIL but at a very low affinity at
physiologic condition [4]. Each homotrimerized TRAILmolecule
engages three receptors, each at the interface of its two sub-
units. Themolecular events downstreamof DR4/DR5 activation
by TRAIL are well described [4–6]. Binding of homotrimerized
TRAIL to its appropriate receptors DR4 and/or DR5 results in
receptor aggregation, recruitment of FADD, FLIP, and procas-
pases 8/10 to form the death-inducing signaling complex
(DISC) leading to caspase 8/10 activation (by autocatalytic
cleavage, the induced proximity hypothesis [7], or by homodi-
merization of the procaspases, the unified model [8]) [9]. The
DISC-activated caspase 8 then activates caspases 3, 6, and 7
by proteolytic cleavages of respective procaspases leading to
induction of apoptosis through a signaling cascade known as
the extrinsic pathway, in contrast to the mitochondria-mediated
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intrinsic death signaling pathway activated following cyto-
toxic stresses [10,11]. Moreover, proteolytically active cas-
pase 8 can also process Bcl2-interacting domain (BID) to
yield truncated BID (tBID), which translocates to the mito-
chondria and, through interaction with Bak and Bax [12–14]
on the mitochondria outer membrane, mediates the release
of multiple proapoptotic proteins including cytochrome c,
apoptosis-inducing factor, and second mitochondria-derived
activator (SMAC/DIABLO), thus linking the extrinsic to the
intrinsic death signaling pathways [10,11,15,16]. Cyto-
chrome c, together with cytosolic apoptotic protease activat-
ing factor 1, procaspase 9, and ATP, forms the apoptosome
that activates caspase 9. Activated caspase 9 processes
caspases 3/7, which proteolytically cleave and activate cas-
pase 8, thus forming a positive amplification feedback loop
to further activate the apical caspase 8 [1]. Death ligand–
mediated induction of apoptosis is further classified into type I
or type II depending on the involvement of the intrinsic
(mitochondria mediated) death signaling cascade in the
effective execution of apoptosis. Type I cells undergo death
receptor–mediated apoptosis independent of mitochondria
(and thus not sensitive to Bcl2/BclXL), whereas type II cells
rely on the intrinsic pathway for efficient apoptosis (and
apoptosis is abrogated by Bcl2, BclXL or by the selective
caspase 9 inhibitor Z-LEHD-fmk) [17].
Recombinant human TRAIL, in its Zn2+-containing homo-
trimer form known as Apo2L/TRAIL (Genentech, Inc., South
San Francisco, CA), in contrast to other forms of recombinant
TRAIL, has been shown to be tumor selective in that it rapidly
and profoundly induces apoptosis of susceptible cancer cells
while sparing normal cells especially primary human hepato-
cytes [3,18,19]. Systemic administrations in nonhuman pri-
mates were well tolerated with no apparent toxicity to the
liver or the bone marrow [19,20]. Malignant tumors of di-
verse histology (cultured cell lines and tumor specimen)
amply express DR4 and/or DR5, yet significant proportions
of receptor-positive cultured cancer cells exhibit resistance
to the cytotoxic effect of Apo2L/TRAIL in vitro [21]. The
molecular basis of this intrinsic or acquired resistance to
TRAIL-induced cytotoxicity in various cancer cell lines is
complex and multifactorial [22]. Fortunately, this limitation
can be overcome by combining recombinant TRAIL receptor
ligand with cancer chemotherapeutic agents (standard cyto-
toxic drugs like cisplatin [23–26], CTP-11 [19], or others
[24,26–29] as well as experimental anticancer drugs [30])
[31,32]. Whereas the underlying mechanisms responsible
for the synergistic interactions between chemotherapeutics
and TRAIL receptor agonists to mediate profound induction
of apoptosis are incompletely understood, it appears that
recruitment/activation of the intrinsic death pathway (mito-
chondria mediated) in combination-treated cells plays the
crucial role [28,33,34].
Histone deacetylase inhibitors (HDACIs) are structurally
diverse chemical compounds that share common biologic
properties of inducing core histone hyperacetylation leading
to gene expression and of mediating potent antitumor effects
[35–37]. Some HDACIs are either naturally occurring com-
pound like sodium butyrate (a fatty acid metabolite found
in high concentration in the lumen of the large intestine) or
a pharmacologic compound such as valproic acid (VA, a
commonly prescribed antiepileptic drug), whereas others are
complex chemicals isolated from culture broths of micro-
organisms (depsipeptide, apicidin, or trichostatin A) or syn-
thetic derivatives (MS-275, CI-994). HDACIs are subdivided
into four fundamental groups: short-chain fatty acids (sodium
butyrate, phenylbutyrate, VA), synthetic benzanides deriva-
tives (MS-275, CI-994), cyclic tetrapeptides (depsipeptide,
trapoxin, apicidin), and hydroxamic acids [trichostatin A,
suberoylanilide hydroxamic acid (SAHA), LAQ8240] [35].
HDACIs induce differentiation, cell cycle arrest, and/or apop-
tosis of cancer cells in culture and in in vivo animal models
[35–37]. Multiple HDACIs (SAHA, depsipeptide, MS275)
have been shown to have anticancer properties in phase I
and II clinical trials [35,38–40]. The antitumor activity of
HDACIs has been attributed to both their ability to inhibit de-
acetylases (leading to accumulation of hyperacetylated his-
tones and alteration of gene transcription) and their ability to
suppress mitogenic signal transduction pathways through
downregulation of oncoprotein expression [41] as well as
their effect on the phenotypic expression of Bax, Bak, Bcl2,
and BclXL leading to a net increase in the ratio of pro- versus
antiapoptotic proteins of the Bcl2 superfamily and the apop-
togenicity of the mitochondria [42–46]. It is the latter property
of HDACIs that we wished to exploit to potentiate the cyto-
toxic effect of Apo2L/TRAIL in cultured thoracic cancer cells
(cancer cell lines derived from tumors of the lung, the eso-
phagus, or the pleura). VA, a commonly prescribed anti-
epileptic drug of which the pharmacokinetics and toxicity
profiles are well documented [47,48], has recently been
shown to be an HDACI [49–51] and to exhibit anticancer
activity in in vitro and in vivo animal models [52–54]. The aim
of this study was to critically evaluate the cytotoxic effect of
the combination of VA and Apo2L/TRAIL in a panel of cul-
tured thoracic cancer cells. We observed that VA + Apo2L/
TRAIL combination synergistically induced profound cyto-
toxicity and apoptosis of cultured thoracic cancer cells
through the mitochondria-dependent (type II) pathway.
Materials and Methods
Cell Lines and Reagents
Cultured non–small cell lung cancer (NSCLC) cells H460
and H322; esophageal cancer (EsC) cells TE2 and TE12;
and malignant pleural mesothelioma (MPM) cells H211 and
H513 were maintained in RPMI 1640 culture medium sup-
plemented with fetal calf serum (10% vol/vol), L-glutamine
(1 mM), and antibiotics [streptomycin (100 mg/ml)/penicillin
(100 U/ml)]. Normal human primary fibroblast and human
umbilical vein endothelial cells (HUVEC) were purchased
from Cambrex Bio Science (Walkerville, MD) and grown in
their special culture media as per instructions of the vendor.
Apo2L/TRAIL was obtained from Genentech Inc. through an
institutional M-CRADA. VA was purchased from Alexis (San
Diego, CA). Selective caspase 8 or caspase 9 inhibitors were
purchased from R&D Systems (Minneapolis, MN). Bcl2-
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overexpressing stable transductants of TE2 (TE2Bcl2) and
H513 (H513Bcl2) cells were created by retrovirally mediated
gene transfer using Bcl2-expressing viral vector containing
green fluorescence protein (GFP) as a selectable marker
(generously provided by P. Robbins, National Cancer Insti-
tute) and previously published transduction techniques [55].
Vector control stable transductants of similar cancer cells
were created using GFP-expressing retrovirus. The magni-
tude of GFP fluorescence in Bcl2 stable transfectants closely
correlated with the level of Bcl2 expression [55]. Cells with
the highest level of GFP were selected by cell sorting for
further culture and expansion. Bcl2 was detected using intra-
cellular staining with phycoerythrin (PE)-conjugated anti-
Bcl2 monoclonal antibody (clone Bcl-2/100, Alexis) after cell
fixation and permeabilization using the Cytofix/Cytoperm kit
from BD Biosciences (San Jose, CA). Flow cytometry con-
firmed 100% of cells expressing high levels of Bcl2. Western
blot analysis demonstrated very high levels of Bcl2 in all
Bcl2-expressing stable transductants.
Flow Cytometric Analysis of TRAIL Receptors
Cancer cells (controls or treatedwith VAat 1.0 or 5.0mM
24 hours) were washed with PBS with 5% BSA and incu-
bated with biotinylated mouse antihuman antibodies for
DR4, DR5, DcR1, and DcR2 (1 mg/500,000 cells; R&D
Systems) for 30 minutes at room temperature. Excess un-
bound antibodies were removed by one wash with PBS and
5% BSA; cells were further incubated with streptavidin-PE
(30 mL/500,000 cells; R&D Systems) for 30 minutes and
washed once before being submitted for flow cytometry.
The levels of receptor expression were quantified by the PE
mean fluorescence intensity index (MFII, the ratio of PEmean
fluorescence intensity of cells incubated with antireceptor
antibody and the backgroundPEmean fluorescence intensity
in cells incubated with IgG isotype control) and the percent-
ages of cells gated positive for receptor expression.
Cytotoxicity and Apoptosis Assays
Cells were seeded in 96-well microtiter plates at prede-
termined plating densities appropriate for each cell line [(1.0–
1.5)  104 cells/well]. After an overnight incubation, cells
were treated with either VA (0.5, 1, or 5 mM) concurrently
with Apo2L/TRAIL (5 to 100 ng/ml; VA + Apo2L/TRAIL) or
12 hours pretreatment of VA followed by addition of Apo2L/
TRAIL in the presence of VA (VA/Apo2L/TRAIL). Cell viability
was quantified by (4,5-dimethylthiazo-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) at 36 hours after the onset of
Apo2L/TRAIL exposure. Cell viability after Apo2L/TRAIL
treatment or combinations of VA and Apo2L/TRAIL treat-
ments were calculated as percentages of untreated controls
or VA-treated controls (to normalize for the very mild growth-
inhibitory effect of VA, which was less than 15% at the highest
concentration of VA at 5mM), respectively. TheApo2L/TRAIL
IC50 values (indices of cellular sensitivity to Apo2L/TRAIL)
were estimated from the respective dose-response curves.
Apoptosis after treatments with Apo2L/TRAIL (10 or 20ng/ml)
alone or in combination with VA (0.5 to 5.0 mM) was deter-
mined by the terminal deoxynucleotidyltransferase-mediated
dUTP nick end labeling (TUNEL)–based Apo-bromodeoxy-
uridine (BrdU) assay (BD Pharmingen, San Jose, CA) for late
apoptosis (48 hours after Apo2L/TRAIL exposure).
Caspase Activity Assay
Specific enzymatic activity of caspases 8, 9, and 3 at
intervals after the onset of treatment with Apo2L/TRAIL (10
or 20 ng/ml) with or without VA (0.5 mM) combination was
measured by a fluorometric kit (R&D Systems). Cells were
treated with VA alone (0.5 mM), Apo2L/TRAIL alone (20 ng/
ml), or VA +Apo2L/TRAIL combination and serially harvested
at 2-hour intervals and assayed for caspase activity. The
specific caspase activity, normalized for total proteins of cell
lysates, was then expressed as fold of the baseline caspase
activity of untreated control cells.
Western Blots
Control or VA-treated cultured thoracic cancer cells were
harvested after 12 hours of VA treatment in Laemmli lysis
buffer for Western blot analysis for the expression of FADD,
pro-caspase 8 (BD Biosciences, 1:250 and 1:500 dilution,
respectively), TRADD (Santa Cruz Biotechnology, Santa
Cruz, CA, 1:200 dilution), FLIP (Alexis, 1:200 dilution), Bax,
Bak, Bcl2 and BclXL, BID (all purchased from Cell Signaling
Technology, Beverly, MA at 1:500 dilution), acetylated his-
tone 3 and histone 4 (Upstate Biotechnology, Waltham, MA
at 1:1000 dilution.). For detection of acetylated histones,
acidic cell lysates were prepared as described in the Web
site of the Chromatin and Gene Expression Group headed
by Prof. Bryan Turner (University of Birmingham, UK; http:
//medweb. bham.ac.uk/research/chromatin/protocol/
extraction.html). Blots were also probed for b-actin (Oncogene
Research Products, Cambridge, MA, 1:5000 dilution) to verify
equal protein loadings. The primary antibodies were probed
with HRP-conjugated antimouse or antirabbit secondary anti-
bodies and detected with West Dura chemiluminescence
(Pierce Biotechnology, Rockford, IL).
Statistical Analysis
Data are presented as means ± SEM of three indepen-
dent experiments each performed in duplicates. Two-tailed
Student’s t test was used for statistical analysis and P values
less than .05 were considered statistically significant.
Results
Mild Growth Inhibitory Effect of VA on Thoracic Cancer
Cells In Vitro
Valproic acid induced significant accumulation of hyper-
acetylated histone protein H3 and H4 in H322, H513, or
TE12 cells (Figure 1A). Continuous exposure of cultured
thoracic cancer cells to VA for 96 hours led to a mild dose-
dependent reduction of cell proliferation (IC50 values ranging
from 3.2 to 5.0 mM; Figure 1A) that was mainly attributable
to induction of cell cycle arrest at G1/S checkpoint (data
not shown) and a weak induction of apoptosis (<15% at
5.0 mM; Figure 1B).
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Synergistic Induction of Cytotoxicity and Apoptosis
by VA and Apo2L/TRAIL Combinations
We next wished to determine if treating thoracic cancer
cells with the combination of VA (at concentrations that are
clinically achievable and have HDAC inhibitory activity) and
Apo2L/TRAIL would mediate synergistic induction of cyto-
toxicity and apoptosis, similar to other more familiar HDACIs.
Intrinsic sensitivity to Apo2L/TRAIL varied greatly between
the six cultured thoracic cell lines used in this study, with
H460, H322, H211, and TE12 cells being sensitive to this
ligand (IC50 values <100 ng/ml) and TE2 and H513 cells
being more refractory to the cytotoxic effect of Apo2L/TRAIL
(IC50 values >150 ng/ml) (Figure 2A). The cytotoxic effect of
high concentrations of Apo2L/TRAIL (100 or 200 ng/ml) in
TE2, TE12, or H513 cells was totally abrogated by Bcl2,
indicating that these were type II cells (Figure 2B). Concur-
rent exposure of cultured thoracic cancer cells to VA (0.5
to 5.0 mM) and Apo2L/TRAIL (5 to100 ng/ml) for 36 hours
resulted in significant supra-additive suppression of cell
viability in MTT assays (representative data for H513,
H460, and TE12 cells are shown in Figure 3A). VA alone,
at the treatment conditions used, mediated little reduction of
viability (15–20% at 5.0 mM). When normalized for this mild
VA-mediated cytotoxic effect, there was substantial further
suppression of cell viability in combination-treated cells
(Figure 3A). Using Apo2L/TRAIL IC50 values as indicators
of cellular sensitivity to this ligand, we found that there
was 1.5- to >10-fold reduction of Apo2L/TRAIL IC50 values
in VA-treated cells in a VA dose–dependent manner
(Figure 3B). This effect was observed in all cultured thoracic
Figure 1. (A) VA-mediated reduction of cell viability of cultured thoracic cancer cells. Data are presented as means ± SEM of four independent experiments.
Accumulation of hyperacetylated histone H3 or H4 in H322, H513, and TE12 cells after 24-hour exposure to VA (either 0.5 or 5.0 mM); blotting for -actin indicated
equal protein loadings. Representative data of two independent experiments with similar results are shown here (B). Mild induction of apoptosis by VA (1.0 or
5.0 mM  48 hours). Apoptosis was quantified by TUNEL-based Apo-BrdU assay. Data are presented as means ± SEM of four independent experiments.
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cancer cells regardless of their intrinsic sensitivity to Apo2L/
TRAIL and particularly most pronounced in Apo2L/TRAIL-
resistant (TE2, TE12, and H513 cells) cell lines. Moreover,
VA treatment did not affect the intrinsic susceptibility of the
Apo2L/TRAIL-sensitive cells H322, H460, and H211 to this
ligand. Most importantly, the VA + Apo2L/TRAIL combina-
tion, although very toxic to cancer cells, was not harmful to
primary cultured normal cells (Figure 3C). Treating cancer
cells with either concurrent (VA + Apo2L/TRAIL) or sequen-
tial VA followed by Apo2L/TRAIL in the presence of VA (VA/
Apo2L/TRAIL) schedule similarly sensitized cancer cells to
Apo2L/TRAIL (Figure 3D). Concurrent VA + Apo2L/TRAIL
combination profoundly and synergistically induced apop-
tosis in thoracic cancer cells, even at VA concentration as
low as 0.5 mM (Figure 4).
The Effect of VA on Expression of TRAIL Receptors
and Proapoptotic Proteins
We next sought to determine if VA increased the expres-
sion of TRAIL receptors DR4, DR5 andDcR1, DcR2, as other
HDACIs have been shown to upregulate TRAIL receptor
expression in cultured cancer cells of different histology
[56–61]. Treating H460, H513, or TE12 cells with VA (5 mM
for 12 hours) did not substantially change the basal expres-
sion of TRAIL receptors in these cells except a two-fold re-
duction of DR4 in H460 cells (Figure 5A). As significant
cytotoxicity was observed after concurrent exposure of can-
cer cells to VA and Apo2L/TRAIL, and knowing that Apo2L/
TRAIL would bind to its cognate receptors and initiate the
signaling cascade within minutes of exposure to receptor-
bearing cells, it is conceivable that alteration of TRAIL re-
ceptor repertoire by VA would not play any significant role
in the process of enhancing the cytotoxic effect of Apo2L/
TRAIL in VA-treated cells. We thus further investigated the
effect of VA on other components of the apoptosis-inducing
apparatus, namely, members of the DISC (FLIP, FADD, pro-
caspase 8) and the mitochondria-associated pro- or anti-
apoptotic proteins (Bax, Bak, Bcl2, BclXL). Time-course
experiments indicated that there was no discernible alteration
of the levels of these proteins in H513, H460, or TE12 cells
continuously treated with VA (1 mM) and harvested at indi-
cated timepoints after the onset of drug exposure (Figure 5B).
We next turned our attention on analyzing the functional
aspect of the caspase cascades in combination-treated cells.
Involvement of the Mitochondria-Dependent Death Signal
Cascade in VA-Mediated Enhancement of Apo2L/TRAIL
Sensitivity
The specific proteolytic activities of caspases 8, 9, and 3
were assayed at intervals after drug treatment in H513 cells
(parental cells or Bcl2-overexpressing stable transfectants
H513Bcl2 cells) after exposure to VA, Apo2L/TRAIL, or
sequential VA/Apo2L/TRAIL combination. Whereas no or
little (zero to four-fold) activation of caspases 8, 9, or 3 was
observed after exposure of H513 cells to VA (0.5 mM) or
Apo2L/TRAIL (20 ng/ml), a supra-additive five- to eight-fold
increase in the activity of these caspases was observed in
cells treated with the VA + Apo2L/TRAIL combination. More
interestingly, treatment-induced activation of not only cas-
pase 9 but also of caspase 8 and caspase 3 was totally
abrogated by overexpression of Bcl2 (Figure 6). Similarly,
complete suppression of the high levels of caspases 8, 9,
and 3 was noted in similarly treated cells incubated with the
selective caspase 9 inhibitor Z-LEHD-fmk (data not shown).
In both experiments, inhibition of caspase 9 activation served
as an internal control, whereas complete inhibition of cas-
pase 3 indicated the exclusive role of the mitochondria
pathway in activating this downstream executioner caspase,
and inhibition of caspase 8 implied activation of this apical
caspase was downstream of caspase 9 and the result of the
amplification feedback loop mediated by the mitochondria-
dependent caspase activation cascade.
Bcl2-mediated inhibition of caspases 8, 9 and 3 activity
was translated to complete abrogation of the intense cyto-
toxic effect of the VA + Apo2L/TRAIL combination in Bcl2
stable transfectants H513Bcl2 and TE12Bcl2 (Figure 7A). The
mild growth-inhibitory effect of Apo2L/TRAIL (20% or 30%
reduction of cell viability in TE12 or H513, respectively) was
Figure 2. (A) Intrinsic susceptibility of cultured thoracic cancer cells to Apo2L/
TRAIL. Cell viability was determined by MTT assay. Apo2L/TRAIL IC50
values of each cell line were derived from the respective cell viability dose-
response curves. Data are presented as means ± SEM of four independent
experiments. (B) Abrogation of cytotoxicity mediated by high concentrations
of Apo2L/TRAIL (100 or 200 ng/ml  36 hours) by overexpression of Bcl2.
Vector control stable transfectants were functionally similar to parental control
cells (data not shown). Data are presented as means ± SEM of four
independent experiments.
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also sensitive to Bcl2 overexpression, indicating that these
were type II cells. The essential role of the mitochondria-
mediated death signal cascade in combination-treated cells
was further evidenced by the complete abrogation of apop-
tosis by the selective caspase 9 inhibitor (Figure 7B).
Discussion
Primary cancers of the thoracic cavity (cancers of the lung,
the esophagus, or the pleura) when presented with re-
gional or systemic metastasis are notoriously refractory to
standard-of-care therapy regimes of cytotoxic chemo-
therapy, external beam irradiation, and surgical resection in
various combinations [62,63]. Better understanding of the
molecular basis of carcinogenesis and elucidation of signal
transduction pathways regulating cell growth and death in
normal cells and their roles in the process of malignant
transformation offers great opportunities for the development
of novel, molecularly targeted anticancer therapy. Within
this context, therapeutic strategies aiming at direct induction
of cell death by activation of the TRAIL receptor–mediated
signal transduction pathways has attracted a great deal of
attention and, in fact, recently entered early-phase clinical
development. Recombinant protein (such as Apo2L/TRAIL
[19] or recombinant human agonistic TRAIL-R1 monoclonal
antibody [64] are commonly used to activate TRAIL receptor
for the induction of apoptosis of cancer cells. It became clear
to investigators in this field that a significant proportion of
cultured malignant cells, although expressing the functional
TRAIL receptors DR4/DR5, are refractory to the cytotoxic
effect of recombinant soluble TRAIL [21]. The molecular
basis of this intrinsic or acquired resistance to TRAIL-
induced cytotoxicity in various cancer cell lines is complex
and multifactorial [21,22]. Moreover, in vitro experimental
conditions can significantly influence the intrinsic suscepti-
bility of cultured cancer cells to TRAIL, thus making deter-
mination of cellular sensitivity to this death-inducing ligand
or others like FasL somewhat arbitrary and subjected to a
wide range of variability between laboratories. We defined
Apo2L/TRAIL-sensitive cells in our study using the described
Figure 3. (A) Dose-dependent enhancement of Apo2L/TRAIL-mediated cytotoxicity by VA (0.5 to 5 mM) in representative cultured thoracic cancer cells H460, TE12,
and H513. Cell viability is expressed as percentages of viable cells in untreated controls (for Apo2L/TRAIL treatment alone) or cells exposed to VA alone (in VA +
Apo2L/TRAIL– treated cells to normalize for the very mild growth-inhibitory effect of VA). Data are presented as means ± SEM of four independent experiments.
(B) Lack of VA + Apo2L/TRAIL– induced cytotoxicity in either primary normal skin fibroblasts or HUVEC. Significant accumulation of acetylated H4 histone
protein was observed in these primary normal cells treated with VA (1.0 or 5.0 mM for 24 hours). Data are presented as means ± SEM of three independent
experiments. (C) Apo2L/TRAIL IC50 values of cultured cancer cells treated with the VA + Apo2L/TRAIL combinations. These values were estimated from the
respective dose-response curves and used as indicators of cellular sensitivity to Apo2L/TRAIL. Data are presented as means ± SEM of four independent
experiments; #P < .001 and *P < .05 versus Apo2L/TRAIL alone. (D) Treatment schedules (concurrent VA and Apo2L/TRAIL or VA pretreatment for 12 hours
before adding Apo2L/TRAIL) have no impact on the enhancement of cellular sensitivity to Apo2L/TRAIL in cell treated with drug combinations. Data are presented
as means ± SEM of four independent experiments.
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Figure 3. (continued)
Figure 4. Profound and synergistic dose-dependent induction of apoptosis by the VA + Apo2L/TRAIL combinations in representative cultured thoracic cancer cells.
Data are presented as means ± SEM of four independent experiments; #P < .001 versus Apo2L/TRAIL alone or VA treatment alone.
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experimental conditions as those with IC50 values less than
100 ng/ml. We have screened about 15 cultured thoracic
cancer cell lines and identified 7 that are intrinsically sen-
sitive to Apo2L/TRAIL (2 NSCLC, 3 EsC, and 2 MPM cell
lines). The cancer cells selected for this study repre-
sented both Apo2L/TRAIL-sensitive as well as Apo2L/
TRAIL-resistant lines.
Previous studies have demonstrated the synergistic
cytotoxicity mediated by HDACIs and TRAIL combinations
[56–60,65–69]. Both leukemic cell lines and those derived
from solid tumors were evaluated in these studies using
different classes of HDACIs. Enhanced TRAIL cytotoxicity
in cells treated with such drug combinations was frequently
attributed to upregulation of DR4/DR5 expression or DISC
assembly leading to increased caspase 8 activation and
apoptosis [56–61,65]. Modulation of the expression of pro-
and antiapoptotic proteins of the Bcl2 superfamily was also
observed in HDACI-treated cells and thought to play a role in
sensitizing cultured cancer cells to the apoptosis-inducing
effect of TRAIL [61,70,71]. Others have demonstrated the
involvement of the intrinsic pathway in mediating enhanced
cytotoxicity after treatment with the HDACI + TRAIL combi-
nation [61,67]. In direct contrast to previously mentioned
publications, we did not observe any alteration of DR4/DR5
expression in VA-treated cells. As profound cytotoxicity was
observed in cells concurrently exposed to TRAIL and HDACI
and HDACI-induced upregulation of DR4/DR5 expression
occurred after latent periods ranging from 4 to 6 hours in
many reported studies, it is hard to attribute receptor up-
regulation as having a direct impact on the enhancement of
cellular sensitivity to TRAIL. Even if there was a delayed up-
regulation of TRAIL receptors in VA-treated cells that was not
readily detected by the flow cytometry method that we used
in our study, such a change would not have an impact on the
enhanced cytotoxicity of this drug combination, as similar
degrees of growth inhibition were observed in cancer cells
treated with either concurrent VA + Apo2L/TRAIL or sequen-
tial VA/Apo2L/TRAIL combinations. Enhancement of Apo2L/
TRAIL tumoricidal activity by VA, either in ligand-sensitive
or -resistant cells, was totally abrogated by either Bcl2 over-
expression or by the selective caspase 9 inhibitor, implying
that the intrinsic pathway was essential in regulating this
process. Data from the caspase activity experiments defined
the regulatory role of the mitochondria-derived caspase 9
(and possibly caspase 3) in amplifying the caspase cascade
by potentiating the activation of caspase 8 after Apo2L/TRAIL
exposure, particularly in the presence of VA. The strong
caspase 8 activation in combination-treated H513 cells may
be the result of increased DISC activity or secondary to ac-
tivation by downstream executioner caspases such as cas-
pase 3. Processing of caspase 3 can bemediated by caspase
8 (extrinsic pathway) or by caspase 9 (intrinsic pathway).
The hierarchical ordering of caspase activation downstream
of caspase 9 has been well described [72]. Caspases 3, 8, 7,
and 10 are all substrates of activated caspase 9; whether
caspase 9 directly processes caspase 8 is not completely
clear, but it is well known that caspase 3 does activate
caspase 8. It is entirely possible that, via caspase 3, cas-
pase 9 indirectly regulates caspase 8 activation. Blocking of
caspase 3 activity using a selective inhibitor would abrogate
caspase 8 activation if this was indeed secondary to a down-
stream caspase-dependent feedback loop, but caspase 3
blockade would not discriminate which pathway downstream
from the DISC (intrinsic versus extrinsic) is responsible for
perpetuation of caspase 8 activation. However, inhibition of
caspase 9 activation by using the selective inhibitor Z-LEHD-
fmk or overexpression of Bcl2 would block both caspase 3
and caspase 8 activation if proteolytic processing of cas-
pase 8 was secondary to caspase 3 activation through
the mitochondria-mediated intrinsic pathway. This was ex-
actly what we observed in that caspase 8 activation in
combination-treated cells was completely suppressed by
either Bcl2 overexpression or the selective caspase 9 inhib-
itor. VA, therefore, through a molecular mechanism yet to be
Figure 5. (A) The effect of VA treatment on the expression of DR4/DR5 and
DcR1/DcR2 on representative H460 NSCLC, TE12 EsC, and H513 MPM
cells. TRAIL receptors were quantified by flow cytometry using biotinylated
primary antibodies plus streptavidin-PE and expressed as mean fluorescence
intensity index. Representative data of two independent experiments with
similar results are shown here. (B). Expression of key components of DISC or
the pro-/antiapoptotic proteins of the Bcl2 superfamily in H513 or H460 cells
at time points after VA (1.0 mM) exposure. Representative data of two
independent experiments with similar results are shown here.
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fully elucidated further, activates the intrinsic pathway of
type II cells to increase the efficacy of Apo2L/TRAIL. As we
have not identified type I cells in our panel of cultured tho-
racic cancer cells, it is not known if VA would activate the
intrinsic signaling cascade to induced Apo2L/TRAIL sensiti-
zation, thus invoking the type II characteristic to potentiate
the cytotoxicity of this ligand in such cell lines. Our attempt to
evaluate the effect of VA on altering phenotypic expressions
of key DISC proteins or some well-described mitochondria-
related pro- and antiapoptotic proteins was not fruitful. This
was in contrast to previous findings of other investigators
as well as of our own observation of profound upregulation of
Bax and/or Bak in conjunction with reduction of the levels of
Bcl2/BclXL shortly after treating the same cancer cells with a
more potent HDACI trichostatin A (Reddy et al., unpublished
data). Functionally, we made similar observations with VA +
Apo2L/TRAIL combinations but were unable to reproduce the
phenotypic alterations of members of the Bcl2 superfamily
after VA treatment. Ongoing studies are being conducted to
define the molecular mechanism by which VA instigates the
mitochondria to sensitize cancer cells to Apo2L/TRAIL. Un-
like other studies in which mitochondria activation after
chemotherapy or TRAIL treatments was evaluated by mito-
chondrial release of cytochrome c, apoptosis-inducing factor,
and SMAC/DIABLO and depolarization of mitochondria
membrane potential (Dcm), we concentrated on evaluating
the catalytic activity of caspase 9 as the functional marker
(‘‘readout’’) of activation of the proapoptotic activity of mito-
chondria.Weevaluated VA in combination with Apo2L/TRAIL
based on its biologic property as an HDACI; yet, the VA-
mediated enhancement effect observed in this drug combi-
nation may be secondary to a separate mechanism entirely
independent of its HDAC inhibitory activity.
In summary, VA, at clinically achievable drug concentra-
tions, profoundly enhances the intrinsic sensitivity of cultured
thoracic cancer cells to Apo2L/TRAIL in vitro. As VA is a
Food and Drug Administration–approved antiepileptic drug
with well-described pharmacokinetics and toxicity profiles
and Apo2L/TRAIL is currently undergoing clinical testing,
this drug combination has a good translational potential and
should be considered for clinical development.
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